321 related articles for article (PubMed ID: 37237260)
41. Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD.
Hanset N; Esteve E; Plaisier E; Johanet C; Michel PA; Boffa JJ; Fievet P; Mesnard L; Morelle J; Ronco P; Dahan K
Kidney Int Rep; 2020 Mar; 5(3):331-338. PubMed ID: 32154454
[TBL] [Abstract][Full Text] [Related]
42. Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
Ishiwatari A; Wakai S; Shirakawa H; Honda K
Transplant Proc; 2018 Oct; 50(8):2565-2568. PubMed ID: 30316399
[TBL] [Abstract][Full Text] [Related]
43. Clinical significance of M
Gong Z; Yuan S; Zhu X; Wang Y; Yu F; Yang D; Xu X; Liu H; Li J; Sun L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Jun; 45(6):693-700. PubMed ID: 32879127
[TBL] [Abstract][Full Text] [Related]
44. Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy.
Netti GS; Infante B; Spadaccino F; Godeas G; Corallo MG; Prisciandaro C; Croce L; Rotondi M; Gesualdo L; Stallone G; Grandaliano G; Ranieri E
J Immunol Res; 2019; 2019():8483650. PubMed ID: 31781684
[TBL] [Abstract][Full Text] [Related]
45. Anti-phospholipase A2 Receptor Antibody in Differentiation and Prognostication of Membranous Nephropathy.
Suthar KS; Vanikar AV; Patel RD; Kanodia KV; Nigam LA; Gandhi PA; Mehta AH
Saudi J Kidney Dis Transpl; 2022; 33(2):280-287. PubMed ID: 37417180
[TBL] [Abstract][Full Text] [Related]
46. Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases.
Hudson R; Rawlings C; Mon SY; Jefferis J; John GT
BMC Nephrol; 2022 Apr; 23(1):134. PubMed ID: 35392837
[TBL] [Abstract][Full Text] [Related]
47. Anti-PLA2R Antibodies in Chinese Patients with Membranous Nephropathy.
Li X; Wei D; Zhou Z; Wang B; Xu Y; Pan J; Yang C; Lu J; Qiu Y
Med Sci Monit; 2016 May; 22():1630-6. PubMed ID: 27179439
[TBL] [Abstract][Full Text] [Related]
48. Analysis of glomerular PLA2R efficacy in evaluating the prognosis of idiopathic membranous nephropathy in the background of different serum anti-PLA2R levels.
Sun Y; Lan P; Feng J; Wang Z; Liu C; Xie L; Yu X
Ren Fail; 2022 Dec; 44(1):731-740. PubMed ID: 35484851
[TBL] [Abstract][Full Text] [Related]
49. Retrospective analysis of
Guo Y; Guo N; Wang J; Wang R; Tang L
Ren Fail; 2021 Dec; 43(1):729-736. PubMed ID: 33904354
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
Lu W; Gong S; Li J; Luo H; Wang Y
Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
[TBL] [Abstract][Full Text] [Related]
51. Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor.
Jatem Escalante E; Segarra Medrano A; Carnicer Cáceres C; Martín-Gómez MA; Salcedo Allende MT; Ostos Roldan H; Agraz Pamplona I
Nefrologia; 2015; 35(5):479-86. PubMed ID: 26306972
[TBL] [Abstract][Full Text] [Related]
52. Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy.
Teisseyre M; Perrochia H; Reboul P; Cariou S; Renaud S; Aglae C; Moranne O
BMC Nephrol; 2020 May; 21(1):196. PubMed ID: 32448215
[TBL] [Abstract][Full Text] [Related]
53. Immunosuppressive Therapy in Primary Membranous Nephropathy with Compromised Renal Function.
Ramachandran R; Prabakaran R; Priya G; Nayak S; Kumar P; Kumar A; Kumar V; Agrawal N; Rathi M; Kohli HS; Nada R
Nephron; 2022; 146(2):138-145. PubMed ID: 34818240
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study.
Zhang S; Huang J; Dong J; Li Z; Sun M; Sun Y; Chen B
Front Immunol; 2023; 14():1156470. PubMed ID: 37187749
[TBL] [Abstract][Full Text] [Related]
55. Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.
Xie Z; Dong W; Li Z; Chen Y; Song L; Li R; Wu Y; Fu L; Liang H; Tao Y; Xie J; Wang W; Liu S; Ye Z; Shi W; Liang X
Nephrology (Carlton); 2020 Mar; 25(3):219-229. PubMed ID: 31900967
[TBL] [Abstract][Full Text] [Related]
56. [Pharmacogenetic testing improves treatment responses in patients with PLA2R-related membranous nephropathy].
Tan T; Zheng Y; Li Y; Zeng Y
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jun; 43(6):1047-1050. PubMed ID: 37439180
[TBL] [Abstract][Full Text] [Related]
57. Distribution spectrum and clinical significance of glomerular exostosin (EXT1) deposits in PLA2R-positive membranous nephropathy.
Liu Z; Wan C; Cao Y; Liu S; Xu Z; Zhang C; Su H
J Nephrol; 2024 Jan; 37(1):149-158. PubMed ID: 37882962
[TBL] [Abstract][Full Text] [Related]
58. The cutoff value and prognosis of anti-PLA2R antibody for idiopathic membranous nephropathy: a single-center retrospective study in China.
Guo H; Yao Y; Zhou J; Wang S; Wang Y; Zheng D
Ren Fail; 2023; 45(2):2253922. PubMed ID: 37724562
[TBL] [Abstract][Full Text] [Related]
59. Serum anti-PLA2R antibody and glomerular PLA2R deposition in Chinese patients with membranous nephropathy: A cross-sectional study.
Pang L; Zhang AM; Li HX; Du JL; Jiao LL; Duan N; Liu Y; Yu D
Medicine (Baltimore); 2017 Jun; 96(24):e7218. PubMed ID: 28614271
[TBL] [Abstract][Full Text] [Related]
60. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.
Bech AP; Hofstra JM; Brenchley PE; Wetzels JF
Clin J Am Soc Nephrol; 2014 Aug; 9(8):1386-92. PubMed ID: 25035272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
